PI-3 kinase p110β: a therapeutic target in advanced prostate cancers

Prostate cancers in the castration-resistant stage are life-threatening because they are not curable in clinic. The novel androgen receptor inhibitor Xandi (Enzalutamide) and the new CYP17 inhibitor Zytiga (Abiraterone) prolonged patient survival only a few months in advanced prostate cancers. There...

Full description

Saved in:
Bibliographic Details
Published in:Am J Clin Exp Urol
Main Authors: Li, Benyi, Sun, Aijing, Jiang, Wencong, Thrasher, J Brantley, Terranova, Paul
Format: Artigo
Language:Inglês
Published: e-Century Publishing Corporation 2014
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4219313/
https://ncbi.nlm.nih.gov/pubmed/25374921
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items